Roche IL-12 kidney cancer trials will continue after meeting with FDA, Genetics Institute.
ROCHE INTERFERON-12 TRIALS FOR KIDNEY CANCER WILL CONTINUE following meetings with FDA's Center for Biologics Evaluation & Research, Genetics Institute and clinical researchers on June 15. Roche has been conducting Phase I trials at several U.S. sites of its subcutaneous-administration, recombinant human interferon-12. Roche's IL-12 is reportedly administered once a week. The National Kidney Cancer Association sent a letter to FDA Commissioner Kessler asking that the Roche trials be continued with close monitoring of patients to watch for emergence of side effects.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth